Welcome to our dedicated page for Novo Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo Nordisk A/S stock.
Novo Nordisk A/S develops, manufactures and markets medicines for serious chronic diseases, with a core franchise in diabetes care and obesity treatment. News for NVO commonly centers on GLP-1 products such as Wegovy, including FDA approvals for new formulations and indications, U.S. launch and access initiatives, and clinical data tied to weight management, cardiovascular risk factors and metabolic liver disease.
Company updates also cover investigational programs such as CagriSema, pipeline results in related therapeutic areas, patient-safety actions involving compounded semaglutide, collaborations with pharmacy or telehealth channels, and capital-allocation matters such as share repurchase activity.
Novo Nordisk (NYSE:NVO) reported second-quarter 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates (CER), and adjusted operating profit of DKK 33,389 million, up 11% at CER. These adjusted growth rates exclude non-recurring impacts from US 340B provision reversals and DKK 6.3 billion of non-cash impairment charges related to intangible pipeline assets, including monlunabant.
For full-year 2026 at CER, Novo Nordisk now expects adjusted sales growth of 0% to -6% and adjusted operating profit growth of 0% to -6%, improved from previous ranges of -4% to -12% for both metrics. According to Novo Nordisk, the upgraded outlook is driven by increased expectations for GLP-1 product sales. On a non-adjusted basis, the mid-points of 2026 sales and operating profit growth guidance at CER would be 5% and 12%, respectively. Full financial results for the first six months of 2026 will be published on 4 August 2026.
Novo Nordisk (NYSE:NVO) provides an update on its share repurchase programme conducted under EU Safe Harbour rules. The 12‑month programme, running from 4 February 2026, targets up to DKK 15 billion in B share buybacks, including up to DKK 11,200,000,010.45 under the tranche initiated 6 May 2026.
From 27 July to 3 August 2026, Novo Nordisk repurchased B shares bringing the accumulated amount under this tranche to 12,305,000 shares for DKK 3,733,256,468. Since 4 February 2026, it has bought back 27,064,179 B shares at an average price of DKK 278.35, totalling DKK 7,533,256,457. Novo Nordisk now holds 44,249,480 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk (NYSE:NVO) reported headline results from the phase 3 ZEUS cardiovascular outcomes trial of once‑monthly ziltivekimab 15 mg in over 6,300 people with ASCVD, CKD and inflammation (hsCRP ≥2 mg/L). Ziltivekimab showed IL‑6 pathway target engagement, with expected reductions in free IL‑6 and hsCRP, but did not reduce major adverse cardiovascular events (MACE) versus placebo (hazard ratio 0.99; 95% CI 0.88–1.11).
Overall adverse event and serious adverse event rates were similar between ziltivekimab and placebo, though serious infections were more frequent with ziltivekimab, and no difference in all‑cause mortality was observed. The outcome will trigger a non‑cash impairment charge in Q3 2026 but will not affect the company’s adjusted operating profit outlook for 2026. Ongoing cardiovascular outcomes trials HERMES (heart failure) and ARTEMIS (post‑acute heart attack) are planned to continue, with readouts expected in the first half of 2027.
Novo Nordisk (NYSE:NVO) is executing a share repurchase programme under EU Safe Harbour rules as part of an overall plan to buy back up to DKK 15 billion of B shares over 12 months starting 4 February 2026.
Under the sub-programme initiated on 6 May 2026, the company may repurchase B shares for up to DKK 11.2 billion through 1 February 2027. From 20–24 July 2026, Novo Nordisk repurchased 960,000 B shares, bringing accumulated purchases under this sub-programme to 11,160,000 shares for DKK 3,362,368,903. As of 24 July 2026, a total of 25,919,179 B shares have been repurchased since 4 February 2026 for DKK 7,162,368,893 at an average price of DKK 276.33. The company now holds 43,104,480 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk (NVO) announced FDA approval of Wegovy HD (semaglutide) 7.2 mg injection on March 19, 2026, for adults with obesity who have tolerated 2.4 mg and need additional weight reduction.
STEP UP showed ~21% average weight loss (efficacy estimand) at 72 weeks and 31.2% of patients reached ≥25% weight loss; common adverse reactions included nausea and dysesthesia (22% in the HD arm).
Novo Nordisk (NYSE:NVO) announced that Wegovy pill (semaglutide), the first oral GLP-1 for adult weight loss, was approved Dec 22, 2025 and is now broadly available across the US via 70,000+ pharmacies and select telehealth providers.
In the OASIS 4 trial Wegovy pill 25 mg showed an average weight reduction of about 17% at 64 weeks if all patients stayed on treatment and about 14% regardless of treatment persistence versus ~3% and ~2% for placebo. Starter pricing begins at $149/month ($5/day) with insured patients paying as little as $25/month.
Novo Nordisk (NVO) presented post hoc REDEFINE 1 analyses at ObesityWeek (Nov 6, 2025) showing investigational CagriSema (2.4 mg/2.4 mg) reduced systolic blood pressure by 10.9 mmHg versus 8.8 mmHg for semaglutide 2.4 mg and 2.1 mmHg for placebo over 68 weeks.
CagriSema allowed ~40% of participants on antihypertensives to reduce or stop medication and lowered hsCRP by 68.9% (versus 55.4% semaglutide, 16.0% placebo). Safety was consistent with the GLP-1 RA class; gastrointestinal adverse events were more frequent with CagriSema.
Summary not available.
Novo Nordisk (NYSE:NVO) has received FDA approval for Wegovy® (semaglutide) 2.4 mg injection to treat adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis. This marks a significant milestone as Wegovy® becomes the first GLP-1 RA approved for MASH treatment.
The approval is based on the Phase 3 ESSENCE trial results, which showed that 63% of Wegovy®-treated patients achieved steatohepatitis resolution compared to 34% on placebo, and 37% showed liver fibrosis improvement versus 22% on placebo. The drug demonstrated strong efficacy with 83.5% of patients maintaining the target dose through Week 72.
This represents Wegovy's fourth FDA-approved indication, following its previous approvals for obesity management, cardiovascular risk reduction, and pediatric obesity treatment. Novo Nordisk has also submitted regulatory applications in the EU and Japan.
Novo Nordisk (NYSE:NVO) has announced a new collaboration with WeightWatchers to expand patient access to FDA-approved Wegovy® starting July 1, 2025. The partnership aims to provide patients with streamlined access to the weight management drug through CenterWell Pharmacy.
The company is introducing a new $299 savings offer for self-paying patients from July 1-31, 2025, following the expiration of their previous $199 offer. After July, the price will increase to $499 per month. The offer will be available through WeightWatchers, Ro, LifeMD, and NovoCare® Pharmacy.
Additionally, Novo Nordisk continues its efforts against illegal knockoff "semaglutide" drugs, having filed nearly 120 lawsuits across 34 states. The company warns about risks associated with compounded versions, particularly those using ingredients from unauthorized Chinese suppliers.